Belite Bio submits Japan NDA for tinlarebant under Sakigake
Belite Bio announced submission of a new drug application to Japan’s Ministry of Health, Labour and Welfare for tinlarebant to treat Stargardt disease type 1 under Sakigake designation.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.